Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 438680, 10 pages
http://dx.doi.org/10.1155/2013/438680
Research Article

Metabolomics Study of Resina Draconis on Myocardial Ischemia Rats Using Ultraperformance Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry Combined with Pattern Recognition Methods and Metabolic Pathway Analysis

Yunpeng Qi,1,2,3 Haiwei Gu,4,5 Yunlong Song,1,2,3 Xin Dong,1,2,3 Aijun Liu,6 Ziyang Lou,1,2,3 Guorong Fan,1,2,3 and Yifeng Chai1,2,3

1Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China
2Shanghai Key Laboratory for Pharmaceutical Metabolite Research, 325 Guohe Road, Shanghai 200433, China
3Shanghai Research Centre for Drug (Chinese Materia Medica) Metabolism, 325 Guohe Road, Shanghai 200433, China
4Jiangxi Key Laboratory for Mass Spectrometry and Instrumentation, East China Institute of Technology, Nanchang, Jiangxi 330013, China
5Department of Anesthesiology & Pain Medicine, University of Washington, Seattle, WA 98195, USA
6Department of Pharmacology, School of Pharmacy, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China

Received 7 February 2013; Revised 24 April 2013; Accepted 24 April 2013

Academic Editor: Roja Rahimi

Copyright © 2013 Yunpeng Qi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Resina draconis (bright red resin isolated from Dracaena cochinchinensis, RD) has been clinically used for treatment of myocardial ischemia (MI) for many years. However, the mechanisms of its pharmacological action on MI are still poorly understood. This study aimed to characterize the plasma metabolic profiles of MI and investigate the mechanisms of RD on MI using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry-based metabolomics combined with pattern recognition methods and metabolic pathway analysis. Twenty metabolite markers characterizing metabolic profile of MI were revealed, which were mainly involved in aminoacyl-tRNA biosynthesis, phenylalanine, tyrosine, and tryptophan biosynthesis, vascular smooth muscle contraction, sphingolipid metabolism, and so forth. After RD treatment, however, levels of seven MI metabolite markers, including phytosphingosine, sphinganine, acetylcarnitine, cGMP, cAMP, L-tyrosine, and L-valine, were turned over, indicating that RD is likely to alleviate MI through regulating the disturbed vascular smooth muscle contraction, sphingolipid metabolism, phenylalanine metabolism, and BCAA metabolism. To our best knowledge, this is the first comprehensive study to investigate the mechanisms of RD for treating MI, from a metabolomics point of view. Our findings are very valuable to gain a better understanding of MI metabolic profiles and provide novel insights for exploring the mechanisms of RD on MI.